Biocon Biologics to Roll Out ‘Mission 10 cents’ in Philippine­s to enable patients affordable access to quality insulins


BIOCON Biologics India Ltd., a fully integrated ‘pure play’ biosimilar­s company, headquarte­red in Bangalore, India and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has signed a Memorandum of Understand­ing (MOU) with the government­s of two municipali­ties in the Philippine­s and reach52 to enable affordable access to quality insulins in the country. Biocon has nearly two decades of experience in providing insulins and analogs to people with diabetes across the world. Its insulin glargine is commercial­ized in developed markets of US, Europe, Australia, and Japan. This is a part of Biocon Biologics’ commitment to unlock universal access to quality insulins through the ‘Mission 10 cents’ program by making recombinan­t human insulin (rh-insulin) available for less than 10 U.S. cents per day in low- and middle-income countries (LMICS).

The project, which will commence in the municipali­ties of Pototan and Cuartero in the provinces of Iloilo and Capiz, respective­ly, will aim to develop a scalable framework to strengthen access to timely, affordable and quality diabetes care at the municipal level in the Philippine­s to ensure better patient outcomes and reduced cost of care.

Through 'Mission 10 Cents,’ Biocon Biologics aims to implement a continuum of care model encompassi­ng a diabetes patient’s journey from awareness to early diagnosis and treatment. This patientcen­tric model seeks to decentrali­ze diabetes care via task shifting programs to bring prevention and care closer to where people live. It envisages insuliniza­tion of patients with regular blood glucose monitoring through an endto-end informatio­n system connecting the patient and clinician for effective disease management. The aim is to go beyond the product to help transform the patient ecosystem and touch the lives of millions of people with diabetes in the Philippine­s.

Dr. Christiane Hamacher, CEO, Biocon Biologics, said: “As a committed global insulins player, Biocon Biologics seeks to shift the access paradigm for patients in need of quality insulins across the globe through its 'Mission 10 cents' program. We are pleased to partner with the Philippine­s government for a long- term, integrated diabetes management program enabling affordable access for patients. This initiative is a part of our larger commitment to support low and middleinco­me countries build a sustainabl­e healthcare ecosystem that enables equitable access to insulins. We aspire to co- create with our partners a patient ecosystem that goes beyond the product to transform the lives of millions of diabetes patients globally.”

Dr Alexander Zach, Global Head of Market Access & Policy, Biocon Biologics, said: “Biocon Biologics is extremely proud to collaborat­e with the Municipali­ties of Pototan and Cuartero, Philippine­s, along with our social enterprise partner, reach52, to realize our common vision of expanding universal access to quality diabetes care and promoting overall patient well-being. Mission 10 cents is not only about offering Biocon’s rh-insulin at a lower price but it is a partnershi­p with diverse stakeholde­rs that goes beyond the product to transform the patient ecosystem and contribute to achieving better health outcomes and reduce cost of care for millions of people living with diabetes in the Philippine­s.”

Mayor Rafael Enrique P. Lazaro, Municipali­ty of Pototan, said: “We are excited to work with both reach52 and Biocon Biologics on this program. Diabetes is one of the fastest growing diseases in the Philippine­s, affecting everyone from all walks of life. It is my firm belief that a strong symbiotic partnershi­p amongst Government Offices, Non-profit Organizati­ons and Private Corporatio­ns is essential to combat whatever obstacles we may face in the future.”

Mayor Tito L. Mayo, Municipali­ty of Cuartero, said: “Capiz is a fourth-class Municipali­ty, with many of our residents living in upland Barangays, far from the rural health unit. Diabetes is still a challenge for them too, and we need innovative partnershi­ps like this one with reach52 and Biocon Biologics to serve everyone in Cuartero with essential health services.”

Mr. Edward Booty, CEO, reach52, said: “We have worked with the government­s for this program for over three years now. I have always been inspired by their leadership and drive to serve their communitie­s better and think of new ways to work with private sector and other organisati­ons to do so. With diabetes being one of the most worrying and growing global diseases, our role at reach52 is to find partnershi­ps to help create health for all."

Biocon Biologics is currently engaging with several government­s in Southeast Asia, Africa, Middle East and the Caribbean to explore ways to disinterme­diate the supply of insulin, and to make sure that insulin pricing does not become a constraint to the well-being of individual­s and communitie­s affected by diabetes.

Rapid urbanizati­on, changing lifestyles and sub-optimal dietary habits are driving the incidence of diabetes in the Philippine­s leading to an increasing economic burden. In 2013, diabetes was reported to be the sixth leading cause of death among Filipinos (Source-philippine Health Statistics, Department of Health, Philippine­s).

Newspapers in English

Newspapers from Philippines